Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

被引:58
|
作者
Garg, Lohit [1 ]
Gupta, Manasvi [2 ]
Sabzwari, Syed Rafay Ali [1 ]
Agrawal, Sahil [3 ]
Agarwal, Manyoo [4 ]
Nazir, Talha [1 ]
Gordon, Jeffrey [1 ]
Bozorgnia, Babak [1 ]
Martinez, Matthew W. [1 ]
机构
[1] Lehigh Valley Hlth Network, Div Cardiol, 1200 S Cedar Crest Blvd, Allentown, PA 18103 USA
[2] Maulana Azad Med Coll, Delhi 110092, India
[3] Brown Univ, Div Cardiol, Providence, RI 02903 USA
[4] Univ Tennessee, Hlth Sci Ctr, Dept Internal Med, Memphis, TN 38163 USA
关键词
Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment; Antiarrhythmic agents; CATHETER ABLATION; RHYTHM-CONTROL; TASK-FORCE; STROKE; RISK; OUTCOMES; AMIODARONE; DIAGNOSIS; GENETICS; EFFICACY;
D O I
10.1007/s10741-018-9752-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
引用
收藏
页码:189 / 197
页数:9
相关论文
共 50 条
  • [1] Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management
    Lohit Garg
    Manasvi Gupta
    Syed Rafay Ali Sabzwari
    Sahil Agrawal
    Manyoo Agarwal
    Talha Nazir
    Jeffrey Gordon
    Babak Bozorgnia
    Matthew W. Martinez
    Heart Failure Reviews, 2019, 24 : 189 - 197
  • [2] Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy
    Olivotto, I
    Cecchi, F
    Casey, SA
    Dolara, A
    Traverse, JH
    Maron, BJ
    CIRCULATION, 2001, 104 (21) : 2517 - 2524
  • [3] Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy
    MacIntyre, Ciorsti
    Lakdawala, Neal K.
    CIRCULATION, 2016, 133 (19) : 1901 - 1905
  • [4] Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy
    Lee, Sang-Eun
    Park, Jin-Kyu
    Uhm, Jae-Sun
    Kim, Jong Youn
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Joung, Boyoung
    HEART, 2017, 103 (19) : 1496 - 1501
  • [5] Impact of Atrial Fibrillation on the Clinical Course of Apical Hypertrophic Cardiomyopathy
    Lee, Sang Eun
    Park, Jin-Kyu
    Uhm, Jae-Sun
    Kim, Jong-Youn
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Joung, Boyoung
    CIRCULATION, 2014, 130
  • [6] What is the impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy?
    Cecchi, F
    Olivotto, I
    CARDIAC ARRHYTHMIAS 2003, 2004, : 29 - 35
  • [7] MANAGEMENT OF ATRIAL-FIBRILLATION IN HYPERTROPHIC CARDIOMYOPATHY
    ROBINSON, K
    STOCKINS, B
    DICKIE, S
    MCKENNA, W
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (02) : A117 - A117
  • [8] Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients
    Lee, Hyun-Jung
    Kim, Hyung-Kwan
    Kim, Minkwan
    Moon, Inki
    Lee, Heesun
    Kim, Bong-Seong
    Han, Kyung-Do
    Park, Jun-Bean
    Hwang, In-Chang
    Yoon, Yeonyee E.
    Kim, Yong-Jin
    Cho, Goo-Yeong
    Ommen, Steve R.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
  • [9] Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy
    Olivotto I.
    Maron B.J.
    Cecchi F.
    Current Cardiology Reports, 2001, 3 (2) : 141 - 146
  • [10] Atrial Fibrillation Prevalence With Mavacamten for Obstructive Hypertrophic Cardiomyopathy
    Jaikumar, Likhitesh
    Biswas, Monodeep
    Kagan, Calvin
    Amara, Richard S.
    Reck, Kim M.
    Shorofsky, Stephen
    Dickfeld, Timm
    Wang, Libin
    See, Vincent Y.
    CIRCULATION, 2023, 148